Affymetrix Provides Johnson & Johnson Pharmaceutical R & D Early Access to New High-Throughput GeneChip(R) Platform

25-Sep-2003

Affymetrix, Inc., announced that Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is the first company to gain early access to the new GeneChip(R) HighThroughputArray (HTA) human genome U133 Array, a standard 96-well plate which will have a GeneChip(R) Human Genome U133 A array in each well.

"Over a decade ago we launched GeneChip technology to change the way researchers examine the genome," said Stephen P.A. Fodor, Ph.D., Chairman and Chief Executive of Affymetrix. "Today we are introducing a new 96-well format to industrialize GeneChip genome research. This new format is designed to speed drug development, reduce costs and help scientists produce more effective, targeted therapies. J&JPRD's leadership in leveraging genomics to improve human life is well known. We're delighted they're our first partner in this industrial format for our GeneChip technology."

The GeneChip HTA system will have the capacity to process hundreds of biological samples per day with minimal human supervision, reducing capital, labor, reagent and array expenses. The GeneChip HTA system adapts the same industry-standard GeneChip technology and content that Affymetrix uses in its cartridges to a standard 96-well microtiter plate, which runs on an automated system built with off-the-shelf robotic components. The GeneChip HTA system automates the most labor intensive steps in GeneChip processing, dramatically reducing the cost per assay. The decrease in cost and increase in throughput makes the GeneChip HTA system well suited for downstream development applications like compound profiling, toxicology and clinical trials.

The components that Affymetrix will provide for the GeneChip HTA system include the HTA 96-well plate, the automated assay derived from Affymetrix' standard gene expression assay, and a software system for tracking samples and data.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances